These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31259738)

  • 1. Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection - a review of currently available results.
    Vysloužil J; Kubová K; Tkadlečková VN; Vetchý D
    Acta Pharm; 2019 Sep; 69(3):297-319. PubMed ID: 31259738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ; Uckun FM
    Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
    Friend DR; Kiser PF
    Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
    Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK
    J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
    Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
    Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.
    Gupta SK; Nutan
    HIV AIDS (Auckl); 2013 Oct; 5():295-307. PubMed ID: 24174883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing.
    das Neves J; Martins JP; Sarmento B
    Adv Drug Deliv Rev; 2016 Aug; 103():20-32. PubMed ID: 26732684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rectal microbicide development.
    McGowan I; Dezzutti C
    Curr Top Microbiol Immunol; 2014; 383():117-36. PubMed ID: 23612991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
    Notario-Pérez F; Ruiz-Caro R; Veiga-Ochoa MD
    Drug Des Devel Ther; 2017; 11():1767-1787. PubMed ID: 28670111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of dapivirine vaginal ring for HIV prevention.
    Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
    Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific microbicides in the prevention of HIV infection.
    Kelly CG; Shattock RJ
    J Intern Med; 2011 Dec; 270(6):509-19. PubMed ID: 21917029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
    Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
    PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in microbicide vaginal rings.
    Malcolm RK; Edwards KL; Kiser P; Romano J; Smith TJ
    Antiviral Res; 2010 Dec; 88 Suppl 1():S30-9. PubMed ID: 21109066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.
    Klasse PJ; Shattock R; Moore JP
    Annu Rev Med; 2008; 59():455-71. PubMed ID: 17892435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaginal microbicides and the prevention of HIV transmission.
    Cutler B; Justman J
    Lancet Infect Dis; 2008 Nov; 8(11):685-97. PubMed ID: 18992405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse transcriptase inhibitors as microbicides.
    Lewi P; Heeres J; Ariën K; Venkatraj M; Joossens J; Van der Veken P; Augustyns K; Vanham G
    Curr HIV Res; 2012 Jan; 10(1):27-35. PubMed ID: 22264043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
    Hankins CA; Dybul MR
    Curr Opin HIV AIDS; 2013 Jan; 8(1):50-8. PubMed ID: 23201856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action.
    Fetherston SM; Boyd P; McCoy CF; McBride MC; Edwards KL; Ampofo S; Malcolm RK
    Eur J Pharm Sci; 2013 Feb; 48(3):406-15. PubMed ID: 23266465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of the vaginal delivery route for antiretrovirals in HIV prevention.
    Ferguson LM; Rohan LC
    Ther Deliv; 2011 Dec; 2(12):1535-50. PubMed ID: 22468220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
    Neff CP; Kurisu T; Ndolo T; Fox K; Akkina R
    PLoS One; 2011; 6(6):e20209. PubMed ID: 21673796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.